Yan Q, Liu J. Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. Haematologica; https://doi.org/10.3324/haematol.2024.287052 [Early view].